2012: Uncertainty in benefit assessments

Presentations (German):

  •  Introduction
  •  Why do surrogate endpoints lead to increased uncertainty?
  •  Certainty of conclusions in the assessment of non-drug and drug interventions? practical examples
  •  Network meta-analyses and indirect comparisons: increased (un)certainty?
  •  Test directives according to §137e Social Code Book V: "Proof", "indication" or "hint" - How much certainty of results is necessary to attest that a method has "potential"?
  •  Is there an added benefit by introducing the category "hint? to describe certainty of results?